Make a donation

Research Updates

Congratulations to the Recipient of the Jointly Funded 2017 Myeloma Canada and Canadian Research Society Research Grant

September 2017

By analyzing protein from drug-sensitive and drug-resistant myeloma cells, Dr. Chang and his team have discovered a novel protein called pMARCKS (phosphorylated myristoylated alanine-rich C-kinase substrate) that is highly expressed in drug-resistant myeloma cells.


A Second Phase III Study Shows That Carfilzomib (Kyprolis®) Significantly Improves Overall Survival in Patients with Relapsed Multiple Myeloma

August 11, 2017

On July 12, 2017, a press release was issued by Amgen regarding the final overall survival (OS) analysis from the ASPIRE clinical trial evaluating the KRd regimen of carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone in relapsed myeloma patients. The ASPIRE study demonstrated a significant improvement in the key secondary endpoint of OS. The endpoint of a clinical trial is the goal of the trial; what a trial is trying to measure or find out. Typical endpoints include measurements of toxicity, response rate, and OS.
Results for the study will be presented at a major medical meeting later this year.

CBC Health Interviews Dr Vincent Rajkumar on Suspension of Pembrolizumab (Keytruda) Trials in Multiple Myeloma

July 24, 2017

"The same drugs that work in one cancer really well might not work in another cancer because each cancer is unique and the effects might be totally different," Dr Rajkumar told CBC Health.


ASCO 2017: Early BCMA CAR T-Cell Therapy Results Look Promising

July 24, 2017

Early results from an ongoing Phase I clinical trial (NCT03090659) in China has 33 out of 35 (94%) patients with relapsed or treatment-resistant (refractory) myeloma in clinical remission (complete or near complete) with only mild side effects.


MCRN 005 – The BOSTON Study Has Officially Begun Recruiting Patients in Canada for the Pivotal Phase III Clinical Trial

July 24, 2017

Informed by the Phase II STOMP (MCRN002) trial led by Dr Nizar Bahlis of Calgary, Karyopharm Therapeutics of Newton, Massachusetts has turned to Canada to lead the Phase III global registration trial for selinexor.


MCRN Canadian-Designed Clinical Trial Inspires a Global Phase III Trial 

April 10, 2017

Inspired by the success of the Phase II MCRN 002 STOMP trial, Karyopharm has turned to MCRN investigators to participate and lead the Phase III global registration trial for selinexor. Only therapies that are effective, safe and have tolerable side effects can proceed to Phase III testing.


The Terry Fox Research Institute Invests $5 Million in Myeloma Research 

March 23, 2017

Myeloma Canada is excited to share with our community the amazing news of the decision by the Terry Fox Research Institute (TFRI) to invest $5 million in the New Brunswick-led Multiple Myeloma Molecular Monitoring (M4) study.

Bringing Game-Changing Therapies to Canadian Patients: Active MCRN Clinical Trials

February 23, 2017

The Myeloma Canada Research Network (MCRN) brings innovative Canadian-designed clinical trials to hundreds of patients in 24 centres in 9 provinces across Canada. Read more for updates on MCRN active clinical trials and a preview of MCRN 004, which will begin recruiting in summer 2017.


First Multiple Myeloma Database for Canada Captures Real-World Patient Evidence 

September 1, 2016

A press conference was held yesterday in Toronto to officially launch the Myeloma Canada Research Network National Multiple Myeloma Database. A first of its kind in Canada, "the Database is a key stepping stone to finding a cure" said Dr Reece